Troponin I and cardiovascular risk prediction in the general population: the BiomarCaRE consortium
暂无分享,去创建一个
A. Peters | V. Salomaa | E. Vartiainen | T. Jørgensen | P. Ridker | R. Schnabel | S. Blankenberg | A. Petersmann | W. Koenig | B. Thorand | P. Brambilla | S. Costanzo | L. Iacoviello | K. Kuulasmaa | G. Veronesi | M. Nauck | F. Kee | J. Kontto | T. Zeller | P. Wild | K. Lackner | J. Yarnell | C. Patterson | B. Everett | F. Ojeda | Brendan M. Everett | N. Makarova | G. Linden | A. Peters | A. Peters
[1] Deepak L. Bhatt,et al. Troponin and Cardiac Events in Stable Ischemic Heart Disease and Diabetes. , 2015, The New England journal of medicine.
[2] Olga V. Demler,et al. Tests of calibration and goodness‐of‐fit in the survival setting , 2015, Statistics in medicine.
[3] J. D. de Lemos,et al. Impact of sex on the prognostic value of high-sensitivity cardiac troponin I in the general population: the HUNT study. , 2015, Clinical chemistry.
[4] A. Jaffe,et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.
[5] J. Manson,et al. B-type natriuretic peptides improve cardiovascular disease risk prediction in a cohort of women. , 2014, Journal of the American College of Cardiology.
[6] G. Felker,et al. N-terminal pro-B-type natriuretic peptide: a risk predictor for all. , 2014, Journal of the American College of Cardiology.
[7] Frank Kee,et al. BiomarCaRE: rationale and design of the European BiomarCaRE project including 300,000 participants from 13 European countries , 2014, European Journal of Epidemiology.
[8] Jennifer G. Robinson,et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2014, Circulation.
[9] Jennifer G. Robinson,et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2014, Circulation.
[10] Marco Geraci,et al. Linear Quantile Mixed Models: The lqmm Package for Laplace Quantile Regression , 2014 .
[11] Marco Geraci,et al. Linear quantile mixed models , 2013, Statistics and Computing.
[12] Paolo Giordani,et al. Three-Way Component Analysis Using the R Package ThreeWay , 2014 .
[13] V. Salomaa,et al. Comparison of Three Troponins as Predictors of Future Cardiovascular Events – Prospective Results from the FINRISK and BiomaCaRE Studies , 2014, PloS one.
[14] R. Schnabel,et al. Association of high-sensitivity assayed troponin I with cardiovascular phenotypes in the general population: the population-based Gutenberg health study , 2014, Clinical Research in Cardiology.
[15] A. Keech,et al. Association of contemporary sensitive troponin I levels at baseline and change at 1 year with long-term coronary events following myocardial infarction or unstable angina: results from the LIPID Study (Long-Term Intervention With Pravastatin in Ischaemic Disease). , 2014, Journal of the American College of Cardiology.
[16] V. Salomaa,et al. High population prevalence of cardiac troponin I measured by a high-sensitivity assay and cardiovascular risk estimation: the MORGAM Biomarker Project Scottish Cohort. , 2014, European heart journal.
[17] R. Prager,et al. PONTIAC (NT-proBNP selected prevention of cardiac events in a population of diabetic patients without a history of cardiac disease): a prospective randomized controlled trial. , 2013, Journal of the American College of Cardiology.
[18] C. Watson,et al. Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. , 2013, JAMA.
[19] S. Solomon,et al. Prognostic value of cardiac troponin I measured with a highly sensitive assay in patients with stable coronary artery disease. , 2013, Journal of the American College of Cardiology.
[20] Shah Ebrahim,et al. [European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)]. , 2013, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.
[21] Fred S Apple,et al. Determination of 19 cardiac troponin I and T assay 99th percentile values from a common presumably healthy population. , 2012, Clinical chemistry.
[22] Shah Ebrahim,et al. European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) , 2012, International Journal of Behavioral Medicine.
[23] N. Cook,et al. Sensitive Cardiac Troponin T Assay and the Risk of Incident Cardiovascular Disease in Women With and Without Diabetes Mellitus: The Women's Health Study , 2011, Circulation.
[24] S. Yusuf,et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. , 2011, Kidney international.
[25] Eric Boerwinkle,et al. Cardiac Troponin T Measured by a Highly Sensitive Assay Predicts Coronary Heart Disease, Heart Failure, and Mortality in the Atherosclerosis Risk in Communities Study , 2011, Circulation.
[26] Holly Janes,et al. Measuring the Performance of Markers for Guiding Treatment Decisions , 2011, Annals of Internal Medicine.
[27] Ewout W Steyerberg,et al. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers , 2011, Statistics in medicine.
[28] A. Khera,et al. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. , 2010, JAMA.
[29] M. Zhan,et al. Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. , 2010, JAMA.
[30] M. Woodward,et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis , 2010, The Lancet.
[31] J. Danesh,et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis , 2010, The Lancet.
[32] C. Schmid,et al. A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.
[33] P. Libby,et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. , 2008, The New England journal of medicine.
[34] Georg Endler,et al. C-reactive protein and all-cause mortality in a large hospital-based cohort. , 2008, Clinical chemistry.
[35] M. Pencina,et al. Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond , 2008, Statistics in medicine.
[36] V. Salomaa,et al. Explaining the decline in coronary heart disease mortality in Finland between 1982 and 1997. , 2005, American journal of epidemiology.
[37] Laura Antolini,et al. Inference on Correlated Discrimination Measures in Survival Analysis: A Nonparametric Approach , 2004 .
[38] Shah Ebrahim,et al. JOINT ESC GUIDELINES 2016 European Guidelines on cardiovascular disease prevention in clinical practice – Web Addenda , 2016 .
[39] V. Salomaa,et al. Decline in Out-of-Hospital Coronary Heart Disease Deaths Has Contributed the Main Part to the Overall Decline in Coronary Heart Disease Mortality Rates Among Persons 35 to 64 Years of Age in Finland: The FINAMI Study , 2003, Circulation.
[40] J. Fox. Effect Displays in R for Generalised Linear Models , 2003 .
[41] H. Tunstall-Pedoe,et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. , 2003, European heart journal.
[42] Jason Wittenberg,et al. Clarify: Software for Interpreting and Presenting Statistical Results , 2003 .
[43] Joseph G. Ibrahim,et al. A partial correlation coefficient and coefficient of determination for multivariate normal repeated measures data , 2001 .
[44] F. Harrell,et al. Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors , 2005 .
[45] F. Harrell,et al. Evaluating the yield of medical tests. , 1982, JAMA.
[46] M. Pencina,et al. Net reclassification improvement: computation, interpretation, and controversies: a literature review and clinician's guide. , 2014, Annals of Internal Medicine.
[47] Jennifer G. Robinson,et al. Reply: 2013 ACC/AHA guideline on the assessment of cardiovascular risk. , 2014, Journal of the American College of Cardiology.
[48] B. Gersh. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis , 2010 .